Activation of the aryl hydrocarbon receptor inhibits the development of experimental autoimmune pancreatitis through IL-22-mediated signaling pathways.
Indigo naturalis
aryl hydrocarbon receptor
autoimmune pancreatitis
indole-3-pyruvic acid
interleukin 22
pancreatic islet α cells
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
11 May 2023
11 May 2023
Historique:
received:
28
11
2022
revised:
22
03
2023
accepted:
04
04
2023
pmc-release:
11
05
2024
medline:
11
5
2023
pubmed:
11
5
2023
entrez:
11
5
2023
Statut:
aheadofprint
Résumé
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor expressed in hematopoietic and non-hematopoietic cells. Activation of the AhR by xenobiotics, microbial metabolites, and natural substances induces immunoregulatory responses. Autoimmune pancreatitis (AIP) is a chronic fibroinflammatory disorder of the pancreas driven by autoimmunity. Although AhR activation generally suppresses pathogenic autoimmune responses, the roles played by the AhR in AIP have been poorly defined. In this study, we examined how AhR activation affected the development of experimental AIP caused by the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Experimental AIP was induced in MRL/MpJ mice by repeated injections of polyinosinic-polycytidylic acid. Activation of the AhR by indole-3-pyruvic acid and indigo naturalis, which were supplemented in the diet, inhibited the development of experimental AIP, and these effects were independent of the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Interaction of indole-3-pyruvic acid and indigo naturalis with AhRs robustly augmented the production of IL-22 by pancreatic islet α cells. The blockade of IL-22 signaling pathways completely canceled the beneficial effects of AhR ligands on experimental AIP. Serum IL-22 concentrations were elevated in patients with type 1 AIP after the induction of remission with prednisolone. These data suggest that AhR activation suppresses chronic fibroinflammatory reactions that characterize AIP via IL-22 produced by pancreatic islet α cells.
Identifiants
pubmed: 37166987
pii: 7145827
doi: 10.1093/cei/uxad040
pmc: PMC10243912
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grants-in-Aid for Scientific Research
ID : 21K15987
Organisme : Kindai University Research Enhancement
ID : KD2208
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Front Immunol. 2020 Aug 07;11:1510
pubmed: 32849515
Cell Mol Gastroenterol Hepatol. 2019;8(3):487-511
pubmed: 31229598
Pancreas. 2020 Jan;49(1):e13-e14
pubmed: 31856100
Clin Rev Allergy Immunol. 2020 Dec;59(3):382-390
pubmed: 32279195
Nat Med. 2016 Jun;22(6):598-605
pubmed: 27158904
Cold Spring Harb Perspect Biol. 2019 Feb 1;11(2):
pubmed: 29038121
Cancer Res. 2016 Mar 1;76(5):1135-45
pubmed: 26759244
Gastroenterology. 2016 Dec;151(6):1206-1217
pubmed: 27769811
Mucosal Immunol. 2016 Sep;9(5):1234-49
pubmed: 26813347
J Immunol. 2017 May 15;198(10):3886-3896
pubmed: 28373582
Int Immunol. 2019 Nov 8;31(12):795-809
pubmed: 31287532
Int J Biol Sci. 2012;8(2):249-57
pubmed: 22253568
J Gastroenterol. 2019 Oct;54(10):891-896
pubmed: 31102012
Clin Exp Immunol. 2020 Dec;202(3):308-320
pubmed: 32880930
World J Gastrointest Pathophysiol. 2016 Feb 15;7(1):108-16
pubmed: 26909233
Gut. 2016 Aug;65(8):1322-32
pubmed: 26964842
Trends Immunol. 2018 Dec;39(12):1005-1020
pubmed: 30409559
Annu Rev Pharmacol Toxicol. 1982;22:517-54
pubmed: 6282188
Immunohorizons. 2020 Nov 5;4(11):688-700
pubmed: 33154038
J Infect Dis. 2010 Sep 15;202(6):853-61
pubmed: 20677943
Int Immunol. 2022 Dec 31;34(12):621-634
pubmed: 36044992
J Exp Med. 2009 Jul 6;206(7):1465-72
pubmed: 19564350
Mod Rheumatol. 2017 May;27(3):381-391
pubmed: 28165852
J Gastroenterol. 2020 May;55(5):565-576
pubmed: 31960143
Gut. 2018 Apr;67(4):728-735
pubmed: 28765476
Cell Rep. 2022 May 10;39(6):110773
pubmed: 35545035
Cell Metab. 2018 Nov 6;28(5):737-749.e4
pubmed: 30057068
J Gastroenterol. 2010 Jun;45(6):584-91
pubmed: 20422433
Trends Immunol. 2018 Nov;39(11):874-889
pubmed: 30401468
Annu Rev Immunol. 2015;33:747-85
pubmed: 25706098
J Immunol. 2015 Oct 1;195(7):3033-44
pubmed: 26297761
Sci Transl Med. 2018 Aug 8;10(453):
pubmed: 30089633
J Immunol. 2018 Dec 15;201(12):3683-3693
pubmed: 30429284
Gut. 2013 Sep;62(9):1373-80
pubmed: 23749606
Mucosal Immunol. 2018 Jul;11(4):1024-1038
pubmed: 29626198
J Gastroenterol. 2020 Feb;55(2):169-180
pubmed: 31529220
Gastroenterology. 2012 Dec;143(6):1670-80
pubmed: 23022954
Clin Exp Allergy. 2009 Apr;39(4):469-77
pubmed: 19222496
J Immunol. 2019 Oct 1;203(7):1830-1844
pubmed: 31492743
Sci Rep. 2020 Sep 16;10(1):14879
pubmed: 32938972
J Exp Med. 2020 Feb 13;217(3):e20192195
pubmed: 32997932
Gastroenterology. 2018 Mar;154(4):935-947
pubmed: 29174928
Nature. 2008 May 1;453(7191):106-9
pubmed: 18362914
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
Immunity. 2013 Aug 22;39(2):372-85
pubmed: 23973224
J Interferon Cytokine Res. 2015 May;35(5):340-50
pubmed: 25760898
Front Immunol. 2021 Jun 24;12:697663
pubmed: 34249001
Int Immunol. 2019 Sep 18;31(10):669-683
pubmed: 31132297
Lancet. 2015 Apr 11;385(9976):1460-71
pubmed: 25481618
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
Immunity. 2018 Jan 16;48(1):19-33
pubmed: 29343438